

Application

Cook 10/623,577

09/14/2005

L21 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:905628 HCAPLUS
 DOCUMENT NUMBER: 141:325776
 ENTRY DATE: Entered STN: 29 Oct 2004
 TITLE: Liquid dosage formulations of donepezil
 INVENTOR(S): Pratt, Raymond
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U.S.
 Ser. No. 232,406.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 INT. PATENT CLASSIF.:
 MAIN: A61K031-445
 US PATENT CLASSIF.: 514319000
 CLASSIFICATION: 1-11 (Pharmacology)
 Section cross-reference(s): 63
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004214863	A1	20041028	US 2003-623577	20030722 <--
WO 2001066114	A1	20010913	WO 2001-US7027	20010305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002040038	A1	20020404	US 2001-947086	20010904
US 6458807	B2	20021001		
US 2003040532	A1	20030227	US 2002-232406	20020903
US 6689795	B2	20040210		
PRIORITY APPLN. INFO.:			US 2000-186744P	P 20000303
			US 2000-197610P	P 20000418
			US 2000-220783P	P 20000725
			US 2001-259226P	P 20010103
			WO 2001-US7027	A1 20010305
			US 2001-947086	A1 20010904
			US 2002-232406	A2 20020903

PATENT CLASSIFICATION CODES:

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004214863	ICM	A61K031-445
	INCL	514319000
US 2004214863	NCL	514/319.000
	ECLA	A61K031/445; A61K031/445+A <--
WO 2001066114	ECLA	A61K031/445+A
US 2002040038	NCL	514/319.000
	ECLA	A61K031/445
US 2003040532	NCL	514/319.000
	ECLA	A61K031/445; A61K031/445+A
OTHER SOURCE(S):		MARPAT 141:325776

ABSTRACT:

The invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or dementia associated with neurol. and/or psychiatric conditions, including epilepsy, brain tumors, brain lesions, multiple sclerosis, Down's syndrome, Rett's syndrome, progressive supranuclear palsy, frontal lobe syndrome, and schizophrenia and related psychiatric disorders; cognitive impairments caused by traumatic brain injury, post coronary artery bypass graft surgery, electroconvulsive shock therapy, and chemotherapy, administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compds. described herein. The invention also describes novel methods for treating and preventing delirium, Tourette's syndrome, myasthenia gravis, attention deficit hyperactivity disorder, autism, dyslexia, mania, depression, apathy, and myopathy associated with diabetes by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compds. described herein. The invention also describes novel methods for delaying the onset of Alzheimer's disease, for enhancing cognitive functions, for treating and preventing sleep apnea, for alleviating tobacco withdrawal syndrome, and for treating the dysfunctions of Huntington's Disease by administering a therapeutically effective amount of at least one of the cholinesterase inhibitor compds. described herein. A preferred cholinesterase inhibitor for use in the methods of the invention is donepezil hydrochloride or ARICEPT. The invention also provides orally administrable liquid dosage formulations comprising cholinesterase inhibitor compds., such as ARICEPT.

SUPPL. TERM: donepezil formulation Aricept nootropic chronic fatigue syndrome
INDEX TERM: Erythrocyte
(acetylcholinesterase activity of; liquid dosage formulations of donepezil)
INDEX TERM: Blood analysis
of (cholinesterase determination in; liquid dosage formulations of donepezil)
INDEX TERM: Fatigue, biological
(chronic fatigue syndrome; liquid dosage formulations of donepezil)
INDEX TERM: AIDS (disease)
Human immunodeficiency virus
(infection; liquid dosage formulations of donepezil)
INDEX TERM: Blood-brain barrier
Diagnosis
Dizziness
Fatigue, biological
Human
Preeclampsia
Sleep disorders
(liquid dosage formulations of donepezil)
INDEX TERM: Nicotinic receptors
ROLE: BSU (Biological study, unclassified); BIOL (Biological study)
(liquid dosage formulations of donepezil)
INDEX TERM: Mental disorder
(mood-affecting; liquid dosage formulations of donepezil)
INDEX TERM: Muscle, disease
Pain

(myalgia; liquid dosage formulations of donepezil)

INDEX TERM: Drug delivery systems
(parenterals; liquid dosage formulations of donepezil)

INDEX TERM: Medical goods
(plasters; liquid dosage formulations of donepezil)

INDEX TERM: Infection
(postinfectious fatigue syndrome; liquid dosage formulations of donepezil)

INDEX TERM: Drug delivery systems
(prodrugs, of cholinesterase inhibitors; liquid dosage formulations of donepezil)

INDEX TERM: Drug delivery systems
(solns.; liquid dosage formulations of donepezil)

INDEX TERM: 50-23-7, Cortisol
ROLE: BSU (Biological study, unclassified); BIOL (Biological study)
(increase in production of; liquid dosage formulations of donepezil)

INDEX TERM: 9000-81-1, Acetylcholinesterase 9001-08-5, Butyrylcholinesterase
ROLE: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; liquid dosage formulations of donepezil)


INDEX TERM: 52-68-6, Metrifonate 57-47-6, Physostigmine 321-64-2, Tacrine 321-64-2D, Tacrine, analogs 357-70-0, Galanthamine 357-70-0D, Galanthamine, derivs. 1668-85-5, Epigalanthamine 1668-85-5D, Epigalanthamine, derivs. 1953-04-4, Galanthamine hydrobromide 16088-19-0, Norneostigmine 41303-74-6, Norgalanthamine 41303-74-6D, Norgalanthamine, derivs. 51581-32-9, Norpyridostigmine 86697-68-9, Fasciculin 101246-68-8, Heptylphysostigmine 475473-11-1, Huperzine
ROLE: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage formulations of donepezil)

IT 50-23-7, Cortisol
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(increase in production of; liquid dosage formulations of donepezil)

RN 50-23-7 HCAPLUS

CN Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 9000-81-1, Acetylcholinesterase 9001-08-5,
Butyrylcholinesterase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; liquid dosage formulations of donepezil)
RN 9000-81-1 HCAPLUS
CN Esterase, acetyl choline (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9001-08-5 HCAPLUS
CN Esterase, choline (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 52-68-6, Metrifonate 57-47-6, Physostigmine
321-64-2, Tacrine 321-64-2D, Tacrine, analogs
357-70-0, Galanthamine 357-70-0D, Galanthamine, derivs.
1668-85-5, Epigalanthamine 1668-85-5D, Epigalanthamine,
derivs. 1953-04-4, Galanthamine hydrobromide 16088-19-0
, Norneostigmine 41303-74-6, Norgalanthamine 41303-74-6D
, Norgalanthamine, derivs. 51581-32-9, Norpyridostigmine
86697-68-9, Fasciculin 101246-68-8, Heptylphysostigmine
475473-11-1, Huperzine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(liquid dosage formulations of donepezil)
RN 52-68-6 HCAPLUS
CN Phosphonic acid, (2,2,2-trichloro-1-hydroxyethyl)-, dimethyl ester (6CI,
8CI, 9CI) (CA INDEX NAME)




RN 57-47-6 HCAPLUS
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-,
methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 321-64-2 HCAPLUS

CN 9-Acridinamine, 1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 321-64-2 HCAPLUS


CN 9-Acridinamine, 1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 357-70-0 HCAPLUS

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 357-70-0 HCAPLUS

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 1668-85-5 HCAPLUS

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6S,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 1668-85-5 HCAPLUS

CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6S,8aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 1953-04-4 HCAPLUS


CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, hydrobromide, (4aS,6R,8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HBr

RN 16088-19-0 HCAPLUS
CN Carbamic acid, dimethyl-, 3-(dimethylamino)phenyl ester (9CI) (CA INDEX NAME)




RN 41303-74-6 HCAPLUS
CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-, (4aS,6R,8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 41303-74-6 HCAPLUS
CN 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-, (4aS,6R,8aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 51581-32-9 HCAPLUS

CN Carbamic acid, dimethyl-, 3-pyridinyl ester (9CI) (CA INDEX NAME)



RN 86697-68-9 HCAPLUS


CN Fasciculin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 101246-68-8 HCAPLUS

CN Carbamic acid, heptyl-, (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 475473-11-1 HCAPLUS

CN 2-Pyrrolidinone, 3-hydroxy-5-[(R)-hydroxyphenylmethyl]-4-phenyl-, (3R,4S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Currently available stereo shown.



L21 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:676603 HCAPLUS

DOCUMENT NUMBER: 135:221315

ENTRY DATE: Entered STN: 14 Sep 2001

TITLE: Methods using cholinesterase inhibitors for the treatment of dementia and other conditions

INVENTOR(S): Pratt, Raymond

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

INT. PATENT CLASSIF.:

MAIN: A61K031-55

SECONDARY: A61K031-445

CLASSIFICATION: 1-11 (Pharmacology)

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066114	A1	20010913	WO 2001-US7027	20010305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001049091	A5	20010917	AU 2001-49091	20010305
EP 1311272	A1	20030521	EP 2001-922272	20010305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003525903	T2	20030902	JP 2001-564766	20010305
US 2002035128	A1	20020321	US 2001-899028	20010706
US 2002035129	A1	20020321	US 2001-947087	20010904
US 6482838	B2	20021119		
US 6576646	B1	20030610	US 2002-54931	20020125
US 2003040532	A1	20030227	US 2002-232406	20020903
US 6689795	B2	20040210		
US 2003153598	A1	20030814	US 2002-321653	20021218
US 2004214863	A1	20041028	US 2003-623577	20030722 <--
US 2004122051	A1	20040624	US 2003-732349	20031211
US 2004180931	A1	20040916	US 2004-806409	20040323
PRIORITY APPLN. INFO.:				
			US 2000-186744P	P 20000303
			US 2000-197610P	P 20000418
			US 2000-220783P	P 20000725
			US 2001-259226P	P 20010103
			WO 2001-US7027	W 20010305
			US 2001-899028	B1 20010706
			US 2001-947086	A1 20010904
			US 2001-947087	A1 20010904
			US 2002-232406	A2 20020903
			US 2002-321653	B1 20021218

PATENT CLASSIFICATION CODES:

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001066114	ICM	A61K031-55
	ICS	A61K031-445
WO 2001066114	ECLA	A61K031/445+A
US 2002035128	NCL	514/319.000
	ECLA	A61K031/445
US 2002035129	NCL	514/319.000
	ECLA	A61K031/445
US 6576646	NCL	514/319.000
	ECLA	A61K031/445; A61K031/445+A
US 2003040532	NCL	514/319.000
	ECLA	A61K031/445; A61K031/445+A
US 2003153598	NCL	514/319.000
	ECLA	A61K031/445; A61K031/445+A
US 2004214863	NCL	514/319.000
	ECLA	A61K031/445; A61K031/445+A
US 2004122051	NCL	514/319.000
	ECLA	A61K031/445; A61K031/445+A
US 2004180931	NCL	514/319.000
	ECLA	A61K031/445; A61K031/445+A

<--

OTHER SOURCE(S): MARPAT 135:221315

ABSTRACT:

The invention describes methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or dementia associated with neurol. and/or psychiatric conditions, including epilepsy, brain tumors, brain lesions, multiple sclerosis, Down's syndrome, Rett's syndrome, progressive supranuclear palsy, frontal lobe syndrome, and schizophrenia and related psychiatric disorders; cognitive impairments caused by traumatic brain injury, post coronary artery bypass graft surgery, electroconvulsive shock therapy, and chemotherapy, administering a therapeutically effective amount of at least one cholinesterase inhibitor. The invention also describes methods for treating and preventing delirium, Tourette's syndrome, myasthenia gravis, attention deficit hyperactivity disorder, autism, dyslexia, mania, depression, apathy, and myopathy associated with diabetes by administering a therapeutically effective amount of at least one cholinesterase inhibitor. The invention also describes methods for delaying the onset of Alzheimer's disease, for enhancing cognitive functions, for treating and preventing sleep apnea, for alleviating tobacco withdrawal syndrome, and for treating the dysfunctions of Huntington's Disease by administering a therapeutically effective amount of at least one cholinesterase inhibitor. A preferred cholinesterase inhibitor is donepezil hydrochloride (Aricept®).

SUPPL. TERM: cholinesterase inhibitor dementia cognition impairment; delirium Tourette syndrome autism cholinesterase inhibitor; myasthenia gravis dyslexia mania cholinesterase inhibitor; attention deficit hyperactivity disorder cholinesterase inhibitor; depression apathy diabetes assocd myopathy cholinesterase inhibitor; Alzheimer disease sleep apnea cholinesterase inhibitor; tobacco withdrawal syndrome cholinesterase inhibitor; Huntington disease cholinesterase inhibitor; donepezil hydrochloride dementia cognition impairment; Aricept dementia cognition impairment

INDEX TERM: Nervous system agents
(cholinesterase inhibitors for treatment of dementia and other conditions)

INDEX TERM: Blood vessel, disease
(dementia caused by; cholinesterase inhibitors for treatment of dementia and other conditions)

INDEX TERM: Mental disorder
(dementia, vascular disease-caused; cholinesterase inhibitors for treatment of dementia and other conditions)

INDEX TERM: Drug delivery systems
(oral; cholinesterase inhibitors for treatment of dementia and other conditions)

INDEX TERM: Drug delivery systems
(tablets; cholinesterase inhibitors for treatment of dementia and other conditions)

INDEX TERM: 120011-70-3, Donepezil hydrochloride
120014-06-4 120014-07-5
120014-08-6 120014-09-7
120014-10-0 120014-11-1
120014-12-2 120014-13-3
172602-64-1 359785-78-7
359785-79-8
ROLE: BAC (Biological activity or effector, except adverse);
BSU (Biological study, unclassified); THU (Therapeutic use);
BIOL (Biological study); USES (Uses)
(cholinesterase inhibitors for treatment of dementia and other conditions)

INDEX TERM: 9001-08-5, Cholinesterase
ROLE: BSU (Biological study, unclassified); BIOL (Biological study)
(cholinesterase inhibitors for treatment of dementia and other conditions)


REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD.

REFERENCE(S): (1) Hasegawa; Folia Pharmacologica Japonica, CAPLUS 2000:65530 1999, V114(6), P327 MEDLINE
(2) Mendez; Journal of Neuro psychiatry and Clinical Neurosciences 1999, V11(2), P268 MEDLINE
(3) Sugimoto; US 4895841 A 1990 HCAPLUS

IT 120011-70-3, Donepezil hydrochloride 120014-06-4
120014-07-5 120014-08-6 120014-09-7
120014-10-0 120014-11-1 120014-12-2
120014-13-3 172602-64-1 359785-78-7
359785-79-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cholinesterase inhibitors for treatment of dementia and other conditions)

RN 120011-70-3 HCAPLUS


CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 120014-06-4 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 120014-07-5 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methylene]- (9CI) (CA INDEX NAME)




RN 120014-08-6 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5-methoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 120014-09-7 HCAPLUS

CN 1H-Inden-1-one, 5,6-diethoxy-2,3-dihydro-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 120014-10-0 HCAPLUS

CN 5H-Indeno[5,6-d]-1,3-dioxol-5-one, 6,7-dihydro-6-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 120014-11-1 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-[(3-nitrophenyl)methyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 120014-12-2 HCAPLUS

CN 1H-Inden-1-one, 2-[[1-(cyclohexylmethyl)-4-piperidinyl]methyl]-2,3-dihydro-5,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 120014-13-3 HCAPLUS

CN 1H-Inden-1-one, 2-[[1-[(3-fluorophenyl)methyl]-4-piperidinyl]methyl]-2,3-dihydro-5,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 172602-64-1 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[3-[1-(phenylmethyl)-4-piperidinyl]propylidene]- (9CI) (CA INDEX NAME)




RN 359785-78-7 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[3-[1-(phenylmethyl)-4-piperidinyl]-1-propenyl]- (9CI) (CA INDEX NAME)



RN 359785-79-8 HCAPLUS

CN 1H-Inden-1-one, 2,3-dihydro-6-methoxy-5-(1-methylethoxy)-2-[3-[1-(phenylmethyl)-4-piperidinyl]-2-propenyl]- (9CI) (CA INDEX NAME)



IT 9001-08-5, Cholinesterase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cholinesterase inhibitors for treatment of dementia and other conditions)

RN 9001-08-5 HCAPLUS

CN Esterase, choline (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***